Legal & General Group
SGMT icon

Legal & General Group’s Sagimet Biosciences SGMT Stock Holding History

Legal & General Group’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,147
Closed -$11.6K – 3499
2024
Q1 		$11.6K Buy
2,147
+1,660
+341% +$11.9K ﹤0.01% 3171
2023
Q4 		$2.64K Hold
487
– – ﹤0.01% 3355
2023
Q3 		$4.29K Buy
+487
New +$6.48K ﹤0.01% 3370

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Legal & General Group's SGMT Position: Q2 2024 in Review

Legal & General Group sold out of Sagimet Biosciences (SGMT) in Q2 2024, closing a stake of 2,147 shares — an estimated $11.6K sold.

Legal & General Group first reported a position in SGMT in Q3 2023 and held it in 3 quarters. The position peaked at $11.6K in Q1 2024. 82 funds tracked by Wall St. Rank hold SGMT as of Q2 2024.

  • Legal & General Group reported no remaining Sagimet Biosciences position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 2,147 Sagimet Biosciences shares in Q2 2024, an estimated $11.6K.
  • Legal & General Group first reported a position in Sagimet Biosciences in Q3 2023 and held it in 3 quarters.
  • Legal & General Group's Sagimet Biosciences position peaked at $11.6K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.